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Abstract
After the first year post transplantation, prognostic mortality scores in kidney transplant
recipients can be useful for personalizing medical management. We developed a new prog-
nostic score based on 5 parameters and computable at 1-year post transplantation. The
outcome was the time between the first anniversary of the transplantation and the patient’s
death with a functioning graft. Afterwards, we appraised the prognostic capacities of this
score by estimating time-dependent Receiver Operating Characteristic (ROC) curves from
two prospective and multicentric European cohorts: the DIVAT (Données Informatisées et
VAlidées en Transplantation) cohort composed of patients transplanted between 2000 and
2012 in 6 French centers; and the STCS (Swiss Transplant Cohort Study) cohort composed
of patients transplanted between 2008 and 2012 in 6 Swiss centers. We also compared the
results with those of two existing scoring systems: one from Spain (Hernandez et al.) and
one from the United States (the Recipient Risk Score, RRS, Baskin-Bey et al.). From the
DIVAT validation cohort and for a prognostic time at 10 years, the new prognostic score
(AUC = 0.78, 95%CI = [0.69, 0.85]) seemed to present significantly higher prognostic
capacities than the scoring system proposed by Hernandez et al. (p = 0.04) and tended to
perform better than the initial RRS (p = 0.10). By using the Swiss cohort, the RRS and the
the new prognostic score had comparable prognostic capacities at 4 years (AUC = 0.77 and
0.76 respectively, p = 0.31). In addition to the current available scores related to the risk to
return in dialysis, we recommend to further study the use of the score we propose or the
RRS for a more efficient personalized follow-up of kidney transplant recipients.
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Introduction
Kidney transplantation (KT) is known to be the treatment of choice for end-stage renal disease.
Population analyses have demonstrated that KT recipients (KTR) have a lower mortality than
patients on dialysis awaiting transplantation [1–4]. However, on an individual level, the mor-
tality risk varies between patients, resulting in a heterogeneity of the benefit in relation to trans-
plantation [5]. This is particularly important with regard to the ageing of recipients, as in the
United States for instance where the proportion of candidates on the KT waiting list over the
age of 65 years has increased during the past decade from 10 to 18% [6].
The stratification of recipients according to their mortality risk could be helpful to clinicians
for personalizing medical management by adapting outpatient follow-up frequency. As an
example, we currently proceed to such adaptation by video-conferencing in the frame of a
French multicenter randomized study [7], in which the visits frequency is driven by the long-
term risk of return to dialysis evaluated by a decision making tool so-called: “Kidney Trans-
plant Failure Score (KTFS)” and computed at 1-year [8]. We voluntarily built the KTFS at one
year post transplantation since it seems difficult to propose such adaptation within the first
months after transplantation when numerous clinical events can frequently occur (infections,
acute rejection episodes, treatment adaptations, etc.). In addition to the prediction of the risk
of return to dialysis, we hypothesized that the combined evaluation with the risk of long-term
mortality could improve the risk stratification for a better medical follow-up adaptation.
In 2009, Hernandez et al. proposed such a risk score computable at 1-year post transplanta-
tion for mortality prediction with a C-index value at 0.74 (95%CI = [0.70, 0.77]) for a prognos-
tic at 3 years since the first anniversary of the transplantation [9]. This retrospective study was
conducted on Spanish patients receiving a KT in 1990, 1994, 1998 and 2002. This score took
into account 8 variables: recipient age at the transplantation, history of diabetes and hepatitis C
virus (HCV), new onset diabetes after transplantation (NODAT), 1-year serum creatinine,
1-year 24h-proteinuria and maintenance immunosuppressive therapy with Tacrolimus or
Mycophenolate Mofetil (MMF) within the first year of transplantation. Nevertheless, to our
knowledge, there is no publication concerning an external validation of this score upon other
cohorts.
In the United States, Baskin-Bey et al. [10] have developed the Recipient Risk Score (RRS)
based on 4 recipient characteristics: recipient age, history of diabetes, cardiac angina and dura-
tion on dialysis therapy. Compared to other pre-transplant scores [11–15], it currently presents
the highest capacities for mortality prediction with a C-statistic at 0.78 for a prognostic at 5
years since the transplantation [16]. Nevertheless, because the RRS only considers recipient
characteristics at the time of transplantation, one can expect that the addition of donor and
transplantation characteristics within the first year post transplantation could improve its
capacities to predict the long term mortality.
The primary objective of our study was to develop an alternative mortality scoring system
calculated at 1-year post transplantation. The secondary aim was to study its prognostic capaci-
ties from twoWestern European cohorts and to compare the corresponding prognostic capaci-
ties with the ones of the both scoring systems proposed by Hernandez et al. [9] and Baskin-Bey
et al. [10].
Materials and Methods
Study population consisting of two distinct cohorts
To conduct this study, we used the prospective French multicentric DIVAT cohort (Données
Informatisées et VAlidées en Transplantation, www.divat.fr). About one third of the kidney
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transplantations performed today in France are included in the DIVAT cohort. Codes were
used to assure patients anonymity and blind assay. The “Comité National Informatique et Lib-
erté” approved the study (N° CNIL 891735) and written informed consent was obtained from
the participants. Patients transplanted between 2000 and 2012 in 6 French University Hospitals
(Nantes, Necker, Nancy, Toulouse, Montpellier and Lyon) and who remained alive with a
functioning graft after one year post transplantation were included in the study. Only adults
receiving a single KT and maintained under Calcineurin inhibitors and MMF for maintenance
therapy after transplantation were considered. Patients with multi-organ transplantation or
with missing values for at least one variable of the scores proposed by Hernandez et al. and Bas-
kin-Bey et al. were excluded. 3439 KTR were included. Patients non-included in the study due
to missing values were compared to the ones included (S1 Table): the two groups appeared to
be comparable.
We also used the prospective multicenter Swiss Transplant Cohort Study (STCS, www.stcs.
ch) [17]. Patients transplanted between 2008 and 2012 in all 6 Swiss University Hospitals
(Basel, Bern, Geneva, Lausanne, Saint-Gall and Zurich) were included. The other inclusion cri-
teria were the same than those used for the French DIVAT cohort. 800 KTR were included.
Since 2008, the STCS cohort has included the totality of the kidney transplantations carried out
in Switzerland.
The flowcharts of each cohort are presented in Fig 1.
Available data
For the French DIVAT cohort, recipient variables were collected at the time of transplantation:
gender, age, body mass index (BMI), time between the registration on the waiting list and
transplantation, time duration on dialysis before transplantation, previous transplants, primary
kidney disease, dialysis modality, cytomegalovirus (CMV) serology, HCV serology, past history
of either diabetes, high blood pressure, cardiovascular event, angina, dyslipidaemia and neopla-
sia. Donor variables extracted were: gender, age, donor type, cause of death, serum creatinine,
and serology (CMV, EBV and HCV). Available transplant data were: cold ischemia time and
number of Human Leukocyte Antigen (HLA) incompatibilities (A-B-DR). Furthermore, the
following variables were collected within the first year post transplantation: NODAT, mainte-
nance therapy with Tacrolimus, 1-year serum creatinine and 1-year 24h-proteinuria.
For the Swiss STCS cohort, only variables taken into account in the RRS and the alternative
1-year prognostic score were extracted from the database.
Note that donor and recipient ethnicities were not available in the two databases and could
therefore not be taken into account.
Data analysis
The construction of a scoring system at 1-year post transplantation. The DIVAT cohort
was randomly divided into two samples for training (two-thirds, n = 2291) and internal valida-
tion (one-third, n = 1148). We checked the comparability of the two samples. The outcome
was the time between the first anniversary of the transplantation and the patient’s death with a
functioning graft (right-censoring of returns to dialysis). We used a semi-parametric Cox
model to construct the score [18]. Univariate analyses were performed in order to make a first
variables selection (p<0.20, training sample). If the log-linearity assumption was unconfirmed,
the variable was categorized according to thresholds traditionally used in the literature. The
selected variables were further analyzed in a multivariable model. The less significant parame-
ters were progressively removed (p<0.05, training sample). Thereafter, clinical relevant inter-
actions were tested. The proportional hazard (PH) assumption was evaluated using weighted
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residuals analysis [19]. In order to obtain predicted probabilities of death for a patient, we
finally estimated the corresponding parametric PH model based on log-likelihood
Fig 1. Flowcharts presenting the steps of the patient inclusion in (A) the French DIVAT cohort and (B) the Swiss
STCS cohort.
doi:10.1371/journal.pone.0155278.g001
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maximization and Weibull distribution (a generalized Weibull distribution was not signifi-
cantly better, likelihood ratio test, p = 0.92). The score corresponded to the normalized linear
predictor of this final model. Calibration curves were generated by plotting non-parametric
observed survival probabilities obtained with the Kaplan-Meier estimator against the mean
individual predicted survival probabilities stratified on predicted risk of death. In order to esti-
mate the net survival curves [20], we used the estimator proposed by Perme, Stare and Estève
[21]. Expected mortality was computed from the lifetime tables available in the human mortal-
ity database (www.mortality.org). Statistical analyses were performed using software R version
3.0.1 with ROCt, nricens, pec and relsurv packages [22].
The evaluation of the prognostic capacities of the scoring systems. Time-dependent
Receiver Operating Characteristic (ROC) curves were estimated [23] from the DIVAT valida-
tion sample and the STCS cohort. The 95% confidence interval of the area under the ROC
curve (AUC) was non-parametrically obtained from 1000 bootstrap replications and by using
the 2.5th and the 97.5th percentiles. The Harrell’s C-index for censored survival data was also
estimated [24, 25] and reported in the S2 Table. Net Reclassification Improvement (NRI) was
applied to evaluate the percentage of patient correctly reclassified into two risk categories [26]:
we chose to define, in an arbitrary manner, the low-risk group by patients with a 5% cumula-
tive probability of death at 10 years since the first anniversary of the transplantation. This
threshold was defined since it seemed an acceptable value for reducing the follow-up for low-
risk patients or, by contrast, increasing the follow-up frequency for high-risk patients.
Results
The French DIVAT cohort characteristics
Among the 2291 KTR of the training sample (Table 1 and Table 2), the mean age was 49.4
(±13.2) years and 62.1% were men. The mean time on dialysis before transplantation was 3.9
(±4.3) years. History of high blood pressure, cardiac angina and past history of diabetes con-
cerned respectively 82.5%, 9.5% and 9.6% of the recipients before transplantation. The mean
donor age was 48.4 (±15.5), 59.3% were men, 12.6% had a creatinine greater than 132 μmol/L
and 51.2% cause of death was vascular brain damage. The median follow-up was 4.5 years
(interquartile range from 2.4 to 7.1). At one year post transplantation, the mean recipient
serum creatinine was 140.0 (±55.7) μmol.L-1. About 10% of patients had a NODAT in the first
Table 1. Recipient, transplantation and donor quantitative characteristics at transplantation or at 1-year of transplantation of the training and vali-
dation samples (mean, standard deviation andmissing values).
Characteristics Training cohort (n = 2 291) Validation cohort (n = 1 148)
Missing* Mean SD Missing* Mean SD
Recipient age (years) 0 (0.0) 49.39 13.17 0 (0.0) 50.09 12.95
Recipient BMI (kg/m2) 17 (0.7) 23.83 4.29 7 (0.6) 23.98 4.24
Waiting time on list (years) 218 (9.5) 2.17 2.15 102 (8.9) 2.22 2.36
Time on dialysis (years) 0 (0.0) 3.89 4.25 0 (0.0) 3.87 4.20
Cold ischemia time (hours) 32 (1.4) 20.00 9.32 14 (1.2) 19.64 9.41
Donor age (years) 12 (0.5) 48.35 15.52 4 (0.3) 47.98 15.74
Donor serum creatinine (μmol.L-1) 81 (3.5) 93.59 53.59 41 (3.6) 93.28 52.10
1-yr serum creatinine (μmol.L-1) 0 (0.0) 139.60 55.69 0 (0.0) 137.80 54.83
Abbreviations: SD, Standard Deviation; BMI, Body Mass Index.
*Missing (effective and %).
doi:10.1371/journal.pone.0155278.t001
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post transplantation year and 7.2% had a 1-year proteinuria higher than 1 g/24h. At 10 years
since the first anniversary of the transplantation, 249 KTR of the training sample returned to
dialysis, 129 died with a functioning graft and 185 remained alive. Regarding the 1148 KTR of
the validation sample, 121 patients returned to dialysis, 69 died and 83 were still followed.
The Swiss STCS cohort characteristics
Among the 800 KTR, the mean age was 51.3 (±13.7) years and 65.6% were men. The mean
time on dialysis before transplantation was 3.5 (±5.2) years. History of cardiac angina and dia-
betes concerned respectively 11.5% and 13.3% of the recipients. The median follow-up was 2.9
years (interquartile range from 1.9 to 3.8). At one year post transplantation, the mean recipient
serum creatinine was 133.0 (±49.4) μmol.L-1. At 4 years since the first anniversary of the trans-
plantation, 21 recipients of the sample returned to dialysis, 31 died with a functioning graft and
2 were still followed. Except for the duration of the follow-up and the sample size, the Swiss
KTR therefore presented a similar profile to the French ones. Patient characteristics of both the
French and the Swiss cohorts are compared in the S3 Table.
The construction of the 1-year scoring system
The aim of this subsection was to study the possibility of a new mortality risk score taking into
account parameters during the first year of transplantation. The survival model obtained from
Table 2. Recipient, transplantation and donor qualitative characteristics at transplantation or at 1-year of transplantation of the training and valida-
tion samples (effective, standard deviation andmissing values).
Characteristics Training cohort (n = 2 291) Validation cohort (n = 1 148)
Missing* Effective % Missing* Effective %
Recipient male gender 0 0.0 1 422 62.1 0 0.0 716 62.4
Rank of the graft  2 0 0.0 507 22.1 0 0.0 259 22.6
Recurrent disease 1 0.1 806 35.2 1 0.1 394 34.4
Hemodialysis 1 0.1 2 082 90.9 0 0.0 1 047 91.2
Positive CMV serology 9 0.4 1 381 60.5 3 0.3 705 61.6
Positive HCV serology 0 0.0 124 5.4 0 0.0 68 5.9
Diabetes 0 0.0 219 9.6 0 0.0 113 9.8
High blood pressure 0 0.0 1 889 82.5 0 0.0 918 80.0
Cardiovascular 0 0.0 880 38.4 0 0.0 453 39.5
Angina 0 0.0 217 9.5 0 0.0 101 8.8
Dyslipidaemia 0 0.0 633 27.6 0 0.0 335 29.2
Neoplasia 0 0.0 196 8.6 0 0.0 96 8.4
Number of HLA-A/B/DR mismatches >4 70 3.1 286 12.9 35 3.0 134 12.0
NODAT 0 0.0 224 9.8 0 0.0 128 11.1
1-yr maintenance therapy with Tacrolimus 0 0.0 1 529 66.7 0 0.0 757 65.9
1-yr 24h-proteinuria > 1g 0 0.0 164 7.2 0 0.0 78 6.8
Donor male gender 20 0.9 1 346 59.3 12 1.0 708 62.3
Deceased donor 5 0.2 2 094 91.6 2 0.2 1 032 90.1
Vascular death of the donor 34 1.5 1 155 51.2 25 2.2 555 49.4
Donor positive CMV serology 13 0.6 1 164 51.1 6 0.5 574 50.3
Donor positive EBV serology 278 12.1 1 862 92.5 127 11.1 942 92.6
Abbreviations: CMV, cytomegalovirus; HCV, Hepatitis C Virus; HLA, Human Leukocyte Antigen; NODAT, New Onset Diabetes After Transplantation;
EBV, Epstein-Barr Virus.
*Missing (effective and %).
doi:10.1371/journal.pone.0155278.t002
Mortality Prognosis in Kidney Transplantation
PLOS ONE | DOI:10.1371/journal.pone.0155278 May 6, 2016 6 / 15
the DIVAT training sub-cohort (n = 2291) is described in Table 3. As expected, recipient age at
transplantation was significantly associated with an excess of mortality post transplantation. In
accordance with the RRS of Baskin-Bey et al. [10], this association seemed different according
to the diabetes status of recipients (p = 0.012). Prolonged waiting time on dialysis before trans-
plantation, past history of cardiovascular events and high value of the 1-year serum creatinine
were also associated with higher mortality (p<0.05). Interestingly, with the exception of the
1-year serum creatinine, all these risk factors were also retained in the RRS proposed by Bas-
kin-Bey et al. [10]. Therefore, the model described in Table 3 can be qualified as an updated
RRS for KTR with a functioning graft at 1-year post transplantation. This score is defined as
the normalized linear predictor of the model, as follows:
1year RRS ¼ f½0:629  recipient age at transplantation ð10 yearsÞþ
3:853  ð1 if pretransplant diabetes and 0 otherwiseÞþ
0:220  time on dialysis ð ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃyearsp Þþ
0:113  value of the 1year serum creatinemia ð
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
mmol:L1
p
Þþ
0:465  ð1 if history of cardiovascular event and 0 otherwiseÞ 
0:608  recipient age at transplantation ð10 yearsÞ  ð1 if pretransplant diabetes and 0 otherwiseÞ  5:06g = 0:99
Thus, a patient with a negative/positive value can be considered to have a post-transplant
risk of death lower/higher than the mean risk observed. Furthermore, approximately 95% of
patients have a score between -2 and 2, and 70% have a score between -1 and 1.
The prognostic capacities of the scoring systems
By using the DIVAT validation sample (n = 1148), Fig 2A shows the areas under ROC curves
associated with the updated 1-year RRS, the RRS proposed by Baskin-Bey et al., the scoring sys-
tem proposed by Hernandez et al., and the recipient age as single predictor. The prognostic
capacities were rather constant for a prognostic time in between 3 and 10 years since the first
anniversary of the transplantation. For the maximal prognostic time up to 10 years, the AUCs
were respectively 0.78 (95%CI = [0.69, 0.85]), 0.74 (95%CI = [0.66, 0.80]), 0.71 (95%CI = [0.64,
0.78]), and 0.71 (95%CI = [0.64, 0.77]). The prognostic capacities of the 1-year RRS in terms of
AUC differences were significantly higher than the recipient age (p = 0.03) and the score
Table 3. Results of the multivariable parametric survival model from the training sample (n = 2291). The scale and the shape parameters of the base-
line Weibull hazard function were respectively equaled 2635.742 (SD = 0.671) and 1.318 (SD = 0.073).
Log HR. (SD) HR 95%CI p-value
Recipient age (10 years) for non-diabetics patients at transplantation 0.629 (0.091) 1.88 [1.57–2.24] <0.001
Recipient age (10 years) for diabetics patients at transplantation 0.021 (0.227) 1.02 [0.65–1.59] 0.927
Time on dialysis (
p
years) 0.220 (0.091) 1.25 [1.04–1.49] 0.016
History of cardiovascular event (Presence/Absence) 0.465 (0.183) 1.59 [1.11–2.28] 0.011
Recipient 1-year serum creatinine (
p
μmol.L-1) 0.113 (0.043) 1.12 [1.03–1.22] 0.008
Abbreviations: SD, Standard Deviation; HR, Hazard Ratio; CI, Conﬁdence Interval.
doi:10.1371/journal.pone.0155278.t003
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proposed by Hernandez et al. (p = 0.04), while they only tended to be higher than initial RRS
(p = 0.10). This trend may be due to the low statistical power tied up to the small number of
deaths (n = 69). Similar results were obtained by using the NRI. Note that we have additionally
performed stratified analyses according to the donor status, which demonstrated the robust-
ness of the RRS applied to living donor patients, even if it was initially developed for deceased
donors.
By using the STCS cohort (Fig 2B, n = 800), 4 years was the maximum prognostic time with
sufficient recipients still at-risk. The AUC related to the updated 1-year RRS for a prognostic
up to 4 years was 0.77 (95%CI = [0.68, 0.85]). No significant difference was highlighted
Fig 2. Area under time-dependent ROC curves according to prognostic time to evaluate the
prognostic capacities of the different markers. (A) The analyses were based on the DIVAT validation
sample (n = 1148). The 1-year updated RRS (black continuous line, 10-year AUC = 0.78, 95%CI = [0.69,
0.85]). The RRS (black dashed line, 10-year AUC = 0.74, 95%CI = [0.66, 0.80]). The score proposed by
Hernandez et al. (grey dotted line, 10-year AUC = 0.71, 95%CI = [0.64, 0.78]). The recipient age (grey
dashed-dotted line, 10-year AUC = 0.71, 95%CI = [0.64, 0.77]). (B) The analyses were based on the STCS
cohort (n = 800). The 1-year updated RRS (black continuous line, 4-year AUC = 0.77, 95%CI = [0.68, 0.85]).
The RRS (black dashed line, 4-year AUC = 0.76, 95%CI = [0.66, 0.83]). The recipient age (grey dashed-
dotted line, 4-year AUC = 0.69, 95%CI = [0.61, 0.76]).
doi:10.1371/journal.pone.0155278.g002
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compared with the RRS (p = 0.31). The prognostic capacities of the Hernandez score could not
be evaluated from the 800 Swiss KTR since some variables of the score were not available in the
database.
Thresholds definition for medical decision-making
For the usefulness of the RRS and the 1-year RRS, it appeared important to suggest thresholds
which could help physicians in medical decision-making, in particular for follow-up adapta-
tion. (Fig 3) We estimated from the DIVAT training sample (n = 2291) that a cut-off at 0.03
for the 1-year RRS and 2.24 for the RRS corresponded to a negative predictive value at 0.95. In
the DIVAT validation sample (n = 1148), we confirmed that patients with a 1-year RRS lower
than 0.03 (n = 527, 46%) or a RRS lower than 2.24 (n = 491, 43%) had less than 5.0% risk of
death up to 10 years since the first anniversary of the transplantation (Fig 3A and 3B). By
removing the expected mortality of a similar population from the general French population
with same gender, age and birth date, the risk of death related to the kidney transplantation sta-
tus was 2.2% in the low-risk group defined by the 1-year RRS (Fig 3C) and 2.0% in the low-risk
group defined by the RRS (Fig 3D). By using the external STCS validation sample (n = 800),
patients with a 1-year RRS lower than 0.03 had 1.6% risk of death up to 4 years since the first
anniversary of the transplantation (Fig 3E, 95%CI = [0.00, 0.03]) and 0.7% for patients with a
RRS lower than 2.28 (Fig 3F: 95%CI = [0.00, 0.02]).
In the DIVAT validation sample, a 1-year RRS value higher than 0.03 was associated with
an all-cause cumulative probability of death at 10 years since the first anniversary of the trans-
plantation at 0.22 (Fig 3A, 95%CI = [0.15, 0.29]). This probability was 0.21 for patients with a
RRS value higher than 2.24 (Fig 3B, 95%CI = [0.15, 0.27]). In the Swiss validation sample, these
probabilities at 4 years were respectively 0.19 (Fig 3E, 95%CI = [0.08, 0.28]) and 0.16 (Fig 3F,
95%CI = [0.07, 0.24]).
Calibration analyses of the 1-year RRS for individual predictions
The mean predicted probabilities of death were very close to the observed ones at 4 and 10
years since the first anniversary of the transplantation by using the DIVAT validation sample
(Fig 4A and 4B, respectively). For the calibration analyses from the Swiss cohort (Fig 4C), the
predicted probabilities of death were also similar for the patients with the lowest risk of death.
In contrast, the 1-year RRS model was associated with an underestimation of the risk of death
for the other two thirds of the recipients. This underestimation was also observable by compar-
ing the patient survival curves for the high-risk patients with a 1-year RRS higher than 0.3 in
both French and Swiss validation samples (Fig 3A and 3E).
Discussion
In kidney transplantation, both prognoses of return to dialysis and death could help to estab-
lish a more personalized follow-up. We believe that the first anniversary of the transplantation
is a relevant landmark to decide the follow-up frequency. On the one hand, the evaluation of
the risk to return to dialysis can be achieved by using the KTFS or other scoring systems [8, 27,
28]. The KTFS is based on 8 clinical and biological factors collected within the first year of
transplantation and aims to stratify patients according to their risk of return to dialysis. It is
currently used in a French clinical trial in which the follow-up frequency is proposed according
to the KTFS estimation [7]. On the other hand, concerning mortality prediction, we firstly
focused in this paper on developing a new scoring system computable at 1-year post transplan-
tation. We secondly studied its prognostic capacities in comparison with the ones obtained by
two other scoring systems [9, 10].
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Fig 3. Patient survival curves according to the two groups defined by the 1-year RRS threshold at 0.03
(A, C, E) or the RRS threshold at 2.24 (B, D, F). (A, B) The analyses concerned the all-cause mortality in the
DIVAT validation sample (n = 1148). (A) The black continuous line corresponds to the low-risk group with a
95.1% probability of being still alive with a functioning graft at 10 years since the first anniversary of the
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This alternative scoring system we proposed is based on 5 parameters which are well-estab-
lished as risk factors of post transplantation mortality [29–36] and close to the ones included in
the initial RRS, except for the 1-year serum creatinine as an additional parameter. Notice that
we did not use the estimated Glomerular Filtration Rate (eGFR) because the recipient age and
gender were already tested as parameters of the score. Notice also that prognostic capacities of
this updated 1-year RRS would have been certainly improve by taking into account patient
reported outcomes, such as compliance, quality of life, stress or depression. However, such
data were unavailable.
Based on the French DIVAT validation cohort, we demonstrated that the prognostic capaci-
ties of the 1-year RRS appeared to be significantly better than the ones of the scoring system
proposed by Hernandez et al. [9]. Additionally, the results indicated that the 1-year RRS out-
performed the recipient age used as single predictor. In accordance with Moore et al. [37], a
score may have a true clinical utility if its prognostic capacities are higher than other simple
and available metric(s), which is obviously the case in our application. Therefore, our results
validated the prognostic capacities for French and Swiss recipients, i.e. for western European
recipients.
Despite the previous validations of the prognostic capacities of the updated 1-year RRS, we
were not able to demonstrate significantly better prognostic capacities than the initial RRS. It
constitutes an additional result in favor of the initial of the pre-transplant RRS which can also
be used at 1 year post-transplantation. Nevertheless, note that a limitation of our study is the
large number of patients non-included (because of missing value for at least one variable of the
prognostic scores) which is likely to decrease the statistical power.
It is also important to note that internal validation (French DIVAT cohort) was performed
for a prognostic time at 10 years while external validation (Swiss STCS cohort) could be per-
formed only at 4 years, owing to an insufficient follow-up duration of the Swiss patients. There-
fore, the 1-year RRS may potentially be more appropriate for use in France and tentatively in
Western Europe, but future studies on largest European KTR cohorts are required. Develop-
ment and validations of the 1-year RRS were based on twoWestern European cohorts. There-
fore its capacities for predicting post-transplantation deaths in countries with different
patients’ characteristics may be challenged and other external validations are needed.
We proposed cut-offs in order to stratify patients into two groups. Patients with a RRS
lower than 2.24 (or with a 1-year RRS lower than 0.03) can be considered at low-risk with a
10-year risk of dying being less than 5%. Based on these results, one can reasonably hypothesize
that recipients classified at low-risk to return to dialysis (assessed for instance by a KTFS level
lower than 4.17) and to die may benefit of a lightened follow-up after the first year post trans-
plantation. These prediction capacities for low-risk patients were validated in terms of
transplantation (95%CI = [90.7, 98.0]). The survival of the high-risk group was estimated at 77.9% (95%CI =
[74.0, 85.4]). The difference between the two curves is highly significant (log-rank test, p<0.001). (B) The
survivals of the low-risk group and the high-risk group were estimated at respectively 95.6% (95%CI = [91.9,
99.5]) and 78.7% (95%CI = [72.7, 85.1]) (log-rank test, p<0.001). (C, D) The analyses concerned the kidney
transplant recipients’ related mortality in the DIVAT validation sample. (C) The black continuous line
corresponds to the low-risk group with a 97.8% probability (95%CI = [95.1, 100.0]). The survival of the high-risk
group is lower with a probability estimated at 89.3% (95%CI = [82.8, 96.3]). (D) The net survivals of the low-risk
group and the high-risk group were estimated at respectively 98.0% (95%CI = [94.1, 100.0]) and 88.1%
(95%CI = [81.3, 95.3]) (E, F) The analysis concerned the all-cause mortality in the STCS cohort (n = 800). (E)
The black continuous line corresponds to the low-risk group with a 98.4% probability of being still alive with a
functioning graft at 4 years since the first anniversary of the transplantation (95%CI = [96.8, 100.0]). The
survival of the high-risk group was estimated at 81.3% (95%CI = [72.1, 91.7]). The difference between the two
curves is highly significant (log-rank test, p<0.001). (F) The survivals of the low-risk group and the high-risk
group were estimated at respectively 99.3% (95%CI = [97.9, 100.0]) and 84.0% (95%CI = [76.3, 92.6]) (log-
rank test, p<0.001).
doi:10.1371/journal.pone.0155278.g003
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Fig 4. Calibration curves of the observed patient survival according to the predicted patient survival
based on the 1-year RRS. (A) Patient survival was estimated from the DIVAT internal validation sample
(n = 1148) at 4 years since the first anniversary of the transplantation. The sample was divided into 5 risk
groups defined by the predicted patient survival. (B) Patient survival was estimated from the DIVAT internal
validation sample (n = 1148) at 10 years since the first anniversary of the transplantation. The sample was
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calibration in both internal and external validation samples. Nevertheless, it is important to
notice that the risk of death was underestimated for Swiss patients classified in the high-risk
group. Therefore, the overall results tended to demonstrate the usefulness of the RRS and the
1-year RRS to accurately identify patients with a low probability of death, the price to pay
being a high percentage of false positive tests, acceptable if our objective is to reduce the follow-
up for low-risk patients and maintain a traditional follow-up for others.
In addition to the adaptation of the follow-up frequency, we believe that the RRS can also be
used to adapt the nature of consultations, i.e. by focusing on modifiable risk factors included in
the RSS. High-mortality risk is particularly attributable to the past history of diabetes and car-
diovascular diseases. The RRS calculation could encourage to enhanced efforts for cardio vas-
cular risk reduction: better glycemia and blood pressure controls and/or reinforced
pharmacologic therapy. It could also guide physicians to better prevent cardiovascular events
with, for instance, specific educational or physical program activities.
In summary, we proposed an updated version of the RRS for patients with functioning graft
at 1-year post transplantation. The latter was internally and externally validated, but no signifi-
cant superiority was evidenced compared to the initial RRS. We also demonstrated the ability
of the pre-transplant RRS for predicting mortality after the first anniversary of the kidney
transplantation and its possible extension to living donor recipients. Therefore, the two scoring
systems may constitute candidates to further increase the efficiency of kidney transplantation
compared to long-term dialysis. Additional studies on larger cohorts should be important for
further validations our results. The 1-year RRS can nevertheless be used from now by using the
application available at www.divat.fr/en/online-calculators.
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